Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VT-105
- Development stage
- Preclinical
- Lead developer
- Versatope Therapeutics
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Unknown, Oral, Intravenous, Intramuscular, Subcutaneous
01
Overview
VT-105 is Versatope Therapeutics' investigational universal influenza A vaccine candidate. It uses recombinant bacterial outer membrane vesicles to display variants of the influenza matrix-2 protein, aiming to stimulate cross-protective immune responses against multiple influenza A strains. The vesicle platform is based on research at Cornell University. Versatope reports that the candidate has received investigational new drug allowance. ([prnewswire.com](https://www.prnewswire.com/news-releases/versatope-selects-influenza-vaccine-candidate-for-clinical-development-301025586.html))
- Other names
- Universal Influenza Vaccine Versatope Therapeutics
Beyond the preview
Go deeper on VT-105.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VT-105.